VP reduced fractured RoM in flexion but was still increased significantly (p < 0.05) above intact kinematic values.
However, existing treatments only reduce fracture susceptibility by 50%.
Bone mineral density testing has been shown to significantly reduce fracture risk.
Antiresorptive agents may reduce fracture risk by several separate but interrelated effects on these individual properties.
Currently, patients with osteoporosis are treated with systemic medications to reduce fracture risk.
Therapeutic strategies have been developed that can reduce fracture susceptibility during osteoporosis to a certain extent.
More trips to the hospital could include intravenous treatments with bisphosphonates, a class of drugs shown to reduce fractures in adults with osteoporosis.
Both oral and intravenous bisphosphonates have been tested in small pediatric studies to help boost bone mineral density and reduce fractures.
She was prescribed hormone replacement therapy (HRT) for nearly 10 years before this was changed to bisphosphonates, a non-hormonal drug that helps maintain bone density and reduce fractures.
Because most women get enough calcium in their diet and because supplementary calcium has not been shown to reduce fractures in otherwise healthy post-menopausal women, the U.S. Preventive Services Task Force does not recommend supplemental calcium.
